Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases

The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: * Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in patients with ras wild type tumours and * Bevacizumab/FOLFOXIRI and FOLFOXIRI in patients with ras mutant tumours.